8/31/2023 0 Comments Prognostic factor![]() Limitations in current prognostic factor research include publication bias, reporting biases, poor statistical analyses, and inadequate replication of initial findings.Prognostic factors have many potential uses: for example, they help define disease at diagnosis, inform clinical and therapeutic decisions (either directly or as part of prognostic models for individualised risk prediction), enhance the design and analysis of intervention trials, and help identify targets for new interventions that aim to modify the course of a disease or health condition.A prognostic factor is any measure that, among people with a given startpoint (such as diagnosis of disease), is associated with a subsequent endpoint (such as death).Why is prognosis research important? More people now live with disease and conditions that impair health than at any other time in history prognosis research provides crucial evidence for translating findings from the laboratory to humans, and from clinical research to clinical practice.However, there is increasing evidence that prognosis research standards need to be improved. What is prognosis research? Prognosis research seeks to understand and improve future outcomes in people with a given disease or health condition.Recommendations are made in each of the four papers to improve current research standards. The PROGRESS series ( ) sets out a framework of four interlinked prognosis research themes and provides examples from several disease fields to show why evidence from prognosis research is crucial to inform all points in the translation of biomedical and health related research into better patient outcomes.As one of the authors is a member of staff at BMJ Group, the handling editor at both journals for the manuscripts was an external guest editor, Dr. In order to disseminate the output widely, these papers are being published jointly between BMJ (PROGRESS papers 1 and 4) and PLOS Medicine (PROGRESS papers 2 and 3). Provenance: Not commissioned externally peer reviewed. The authors declare no other competing interests. ![]() The views expressed in this paper are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.Ĭompeting interests: SS is a full time employee of the BMJ Group but is not involved in the decision making on manuscripts. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The work of HH, AH and ADT is supported by the Health eResearch Centre Network (HERC-UK), funded by The Medical Research Council, in partnership with Arthritis Research UK, the British Heart Foundation, Cancer Research UK, the Economic and Social Research Council, the Engineering and Physical Sciences Research Council, the National Institute of Health Research, the National Institute for Social Care and Health Research (Welsh Assembly Government), the Chief Scientist Office (Scottish Government Health Directorates) and the Wellcome Trust. KA holds a UK National Institute of Health Research Senior Investigator Award (NI-SI-0508-10061). EWS was supported by The Netherlands Organization for Scientific Research (grant 9120.8004) and the Center for Translational Molecular Medicine (PCMM project, grant 03O-203). KGMM is supported by The Netherlands Organization for Scientific Research (ZON-MW 94). JAH is supported by a New Investigator Award from the Canadian Institutes of Health Research and a grant from the Nova Scotia Health Research Foundation she holds a Dalhousie University/CCRF Research Professorship. HH is supported by grants from the UK National Institute for Health Research (RP-PG-0407-10314 ) and the Wellcome Trust (086091/Z/08/Z ). DGA is supported by a programme grant from Cancer Research UK (C5529). RDR is supported by the MRC Midlands Hub for Trials Methodology Research, at the University of Birmingham (Medical Research Council Grant ID G0800808). This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.įunding: This series had no explicit funding but some of the authors were supported by research grants: PROGRESS is supported by a Partnership grant from the Medical Research Council (G0902393), involving UCL (HH,AH), Oxford (DGA), Birmingham (RDR) London School of Hygiene and Tropical Medicine (IR, PP) and Keele (PC, DvdW) and Queen Mary University London (ADT). PLoS Med 10(2):Ĭopyright: © 2013 Riley et al. (2013) Prognosis Research Strategy (PROGRESS) 2: Prognostic Factor Research. Citation: Riley RD, Hayden JA, Steyerberg EW, Moons KGM, Abrams K, Kyzas PA, et al. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |